Hepion Pharmaceuticals (HEPA) 10-Q 14 May 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2015	4-May-15
Document and Entity Information
Entity Registrant Name	ContraVir Pharmaceuticals, Inc.
Entity Central Index Key	1583771
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-24
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,273,397
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2015	Jun. 30, 2014
Current Assets:
Cash	$8,901,298	$1,817,757
Prepaid expenses	460,302	164,421
Total Current Assets	9,361,600	1,982,178
Property and equipment, net	86,606	14,526
Other assets	51,344	4,200
Total Assets	9,499,550	2,000,904
Current Liabilities:
Accounts payable	1,312,991	243,896
Accrued expenses	302,706	207,915
Due to Synergy		6,928
Total Current Liabilities	1,615,697	458,739
Derivative financial instruments, at estimated fair value-warrants		4,475,345
Total Liabilities	1,615,697	4,934,084
Stockholder's Equity:
Common stock, par value of $.0001 per share. Authorized 120,000,000 shares, issued and outstanding 22,273,397 and 18,479,279 shares at March 31, 2015 and June 30, 2014, respectively	2,228	1,848
Additional paid-in capital	16,420,281	2,486,309
Accumulated deficit	-22,238,656	-5,421,337
Total Stockholders' Equity (Deficit)	7,883,853	-2,933,180
Total Liabilities and Stockholders' Equity	9,499,550	2,000,904
Convertible preferred stock
Stockholder's Equity:
Convertible preferred stock
Series A convertible preferred stock
Stockholder's Equity:
Convertible preferred stock	12,500,000
Series B convertible preferred stock
Stockholder's Equity:
Convertible preferred stock	$1,200,000

CONDENSED_BALANCE_SHEETS_PAREN

CONDENSED BALANCE SHEETS (PARENTHETICAL) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	22,273,397	18,479,279
Common stock, shares outstanding	22,273,397	18,479,279
Convertible preferred stock
Convertible preferred stock, par/stated value (in dollars per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	20,000,000	20,000,000
Series A convertible preferred stock
Convertible preferred stock, par/stated value (in dollars per share)	$10
Convertible preferred stock, shares issued	1,250,000	0
Convertible preferred stock, shares outstanding	1,250,000	0
Series B convertible preferred stock
Convertible preferred stock, par/stated value (in dollars per share)	$10
Convertible preferred stock, shares issued	120,000	0
Convertible preferred stock, shares outstanding	120,000	0

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Costs and Expenses:
Research and development	$2,606,032	$72,507	$4,813,747	$95,353
General and administrative	1,791,794	386,463	3,771,031	707,243
Loss from Operations	-4,397,826	-458,970	-8,584,778	-802,596
Interest expense		-6,355		-12,946
Change in fair value of derivative instruments-warrants		-8,846,434	-387,898	-8,846,434
Total Other Loss		-8,852,789	-387,898	-8,859,380
Net loss	-4,397,826	-9,311,759	-8,972,676	-9,661,976
Series A and B convertible preferred stock beneficial conversion feature accreted as a dividend	-3,000,000		-7,844,643
Net loss attributable to common stockholders	($7,397,826)	($9,311,759)	($16,817,319)	($9,661,976)
Weighted Average Common Shares Outstanding
Basic and Diluted (in shares)	22,273,397	14,735,551	20,334,797	10,904,873
Net Loss per Common Share
Basic and Diluted (in dollars per share)	($0.20)	($0.63)	($0.44)	($0.89)

CONDENSED_STATEMENT_OF_CHANGES

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Series A convertible preferred stock	Series B convertible preferred stock	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
	Preferred Stock	Preferred Stock
Balance at Jun. 30, 2014			$1,848	$2,486,309	($5,421,337)	($2,933,180)
Balance (in shares) at Jun. 30, 2014			18,479,279
Increase (Decrease) in Stockholders' Equity
Stock based compensation expense				1,188,988		1,188,988
Stock options granted in excess of authorized limit				-81,689		-81,689
Reversal of stock option liability upon increase in authorized number of shares				119,167		119,167
Restricted common shares issued in exchange of warrants			380	4,862,863		4,863,243
Restricted common shares issued in exchange of warrants (in shares)			3,794,118
Issuance of shares	12,500,000					12,500,000
Issuance of shares (in shares)	1,250,000
Issuance of shares		1,200,000				1,200,000
Issuance of shares (in shares)		120,000
Net loss for the period					-8,972,676	-8,972,676
Beneficial conversion feature accreted as a deemed dividend				7,844,643	-7,844,643
Balance at Mar. 31, 2015	$12,500,000	$1,200,000	$2,228	$16,420,281	($22,238,656)	$7,883,853
Balance (in shares) at Mar. 31, 2015	1,250,000	120,000	22,273,397

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOW (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities:
Net loss	($8,972,676)	($9,661,976)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation expense	1,188,988	144,075
Cost of license as research and development expense	1,200,000
Change in fair value of derivative instruments-warrants	387,898	8,846,434
Depreciation expense	11,189
Changes in operating assets and liabilities:
Prepaid expenses and other assets	-343,026	118,279
Accounts payable, accrued expenses and due to Synergy	1,194,437	-117,452
Total Adjustments	3,639,486	8,991,336
Net cash used in Operating Activities	-5,333,190	-670,640
Cash Flows From Investing Activities:
Additions to property and equipment	-83,269	-15,847
Net cash used in Investing Activities	-83,269	-15,847
Cash Flows From Financing Activities:
Issuance of preferred stock	12,500,000
Issuance of common stock via private placement		3,225,000
Fees and expense - private placement		-15,033
Borrowings under demand note payable to Synergy		350,000
Repayments under demand note payable to Synergy		-450,000
Net cash provided by Financing Activities	12,500,000	3,109,967
Net increase in cash	7,083,541	2,423,480
Cash at beginning of period	1,817,757	86,716
Cash at end of period	8,901,298	2,510,196
Supplementary disclosure of non cash transactions:
Cash paid for interest		12,945
Deemed dividend on preferred stock beneficial conversion feature	7,844,643
Value of warrants exchanged for common stock	$4,863,243

Business_Overview

Business Overview	9 Months Ended
	Mar. 31, 2015
Business Overview
Business Overview
	1. Business Overview
	ContraVir Pharmaceuticals Inc. (“ContraVir” or the “Company”) is a biopharmaceutical company focused primarily on the clinical development of FV-100 to treat herpes zoster (HZ), or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV) or “chickenpox”, and CMX157 to treat Hepatitis B (HBV).
	Convertible Preferred Share Issuance
	On October 14, 2014, December 23, 2014, February 10, 2015 and February 26, 2015, the Company, issued 1,250,000 shares of Convertible Series A preferred shares at a stated value of $10.00 per share, generating gross proceeds of approximately $12,500,000. See Note 4 for the terms of the Preferred Shares and accounting of these transactions.
	On December 15, 2014, the Company entered into a license agreement with Chimerix, Inc. and issued 120,000 shares of Series B Convertible Preferred Stock (the “Series B”) in connection with the license of CMX157 from Chimerix for further clinical development and commercialization. See Note 4 for the terms of the Preferred Shares and accounting of this transaction and Note 8 for license related information.

Basis_of_Presentation_and_Goin

Basis of Presentation and Going Concern	9 Months Ended
	Mar. 31, 2015
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern
	2. Basis of Presentation and Going Concern
	The unaudited condensed financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and United States generally accepted accounting principles (“GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly ContraVir’s interim financial information. The accompanying unaudited financial statements should be read in conjunction with the audited financial statements as of and for the periods ended June 30, 2014 contained in the Company’s Annual Report on Form 10-K (“Form 10-K”) filed with the Securities and Exchange Commission (“SEC”) on September 29, 2014 and the audited financial statement as of and for the periods ended December 31, 2014 contained in the Company’s Quarterly Report on Form 10-Q (“Form 10-Q”) filed with the SEC on February 12, 2015.
	Going Concern
	As of March 31, 2015, ContraVir had $8.9 million in cash. Net cash used in operating activities was $5.3 million for the nine months ended March 31, 2015.  Net loss for the nine months ended March 31, 2015 was $9.0 million. As of March 31, 2015, ContraVir had working capital of $7.7 million. The Company expects to incur losses for the next several years as it expands its research, development and clinical trials of FV-100 and CMX157. The Company is unable to predict the extent of any future losses or when the Company will become profitable, if at all.
	The statements as of March 31, 2015 and June 30, 2014 have been prepared under the assumption that the Company will continue as a going concern. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt in the Company’s ability to continue as a going concern without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company will be required to raise additional capital to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize its self on unfavorable terms.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
	Cash
	As of March 31, 2015 and June 30, 2014, the amount of cash was approximately $8.9 million and $1.8 million, respectively, consisting of checking accounts held at U.S. commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced losses related to these balances.
	Fair Value of Financial Instruments
	ASC Topic 820, Fair Value Measurement (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances.
	ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:
		·	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
		·	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
		·	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
	To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Financial instruments consist of cash, accounts payable and derivative instruments. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments, which were marked to market at the end of each reporting period. See Note 4 for additional information.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Mar. 31, 2015
Recent Accounting Pronouncements
Recent Accounting Pronouncements
	3. Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company early adopted this guidance as of September 30, 2014, which did not have a material impact on the Company’s financial statements.

Stockholders_Equity_and_Deriva

Stockholder's Equity and Derivative Liability	9 Months Ended
	Mar. 31, 2015
Stockholder's Equity and Derivative Liability
Stockholder's Equity and Derivative Liability
	4. Stockholder’s Equity and Derivative Liability
	Warrants
	On February 4, 2014, ContraVir entered into a securities purchase agreement with accredited investors for gross proceeds of $3,225,000 in a private placement and incurred expenses of approximately $15,000 related to this placement. The Company sold 9,485,294 units to the investors with each unit consisting of one share of our common stock and one warrant to purchase an additional one half share of our common stock. The purchase price paid by the investor was $0.34 for each unit. The warrants expire after six years and are exercisable at $0.37 per share. Based upon the criteria contained in ASC Topic 815-40, the Company has determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in the Company’s statement of operations. Upon the issuance of these warrants the fair value of $879,557 was recorded as derivative liability warrants.
	On August 20, 2014, ContraVir consummated its offer (the “Offer”) to exchange an aggregate 4,742,648 outstanding common stock purchase warrants (the “Warrants”) owned by the February 4, 2014 investors in the Company for an aggregate 3,794,118 shares of restricted common stock. The Warrants were revalued on August 20, 2014, immediately prior to conversion increasing the liability by $387,898 to $4,863,243 which was recorded on the change in fair value of derivative instruments- warrants on the statement of operations. The liability was extinguished when the restricted shares were issued that had a fair value of $4,552,924 (using $1.20 per share, which was the stock price on August 20, 2014) by recording the offset to additional paid in capital.
	The following table sets forth the components of changes in the ContraVir’s derivative financial instruments liability balance for the periods indicated:
	Date	Description		Warrants		Derivative
						Instrument
						Liability
	7/1/14	Balance of derivative financial instruments liability		4,742,648		$	4,475,345
		Change in fair value of warrants immediately prior to conversion, recognized as change in fair value of derivative instruments- warrants in the statement of operations		—		387,898
		Amounts reclassified to additional paid-in capital		4,742,648		(4,863,243		)
	3/31/15	Balance of derivative financial instruments liability		—		$	—
	ContraVir’s warrants contained a price protection clause which variable term required the Company to use a binomial model to determine fair value. The range of assumptions used to determine the fair value of the warrants on August 20, 2014 was as follows:
		August 20, 2014
	Estimated fair value of ContraVir common stock	$	1.20
	Expected warrant term (years)	5.46 years
	Risk-free interest rate	1.75		%
	Expected volatility	88		%
	Dividend yield	—
	In the Binomial model, the assumption for estimated fair value of the stock was based on a Black-Scholes based apportionment of the unit price paid for the shares and warrants issued in ContraVir’s recent private placement, which resulting stock prices were deemed to be arms-length negotiated prices. Because the ContraVir has a limited trading history in its common stock, the Company based expected volatility on that of comparable public development stage biotechnology companies. The warrants have a transferability provision and based on guidance provided in SAB 107 for instruments issued with such a provision, ContraVir used the full contractual term as the expected term of the warrants. The risk free rate is based on the U.S. Treasury security rates for maturities consistent with the expected remaining term of the warrants.
	ContraVir Fair Value Measurements
	The following table presents the Company’s liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 30, 2014. There are no such derivative liabilities as of March 31, 2015.
	Description	Balance as of			Quoted Prices			Significant		Significant
		June 30. 2014			in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical			Inputs		(Level 3)
					Assets and			(Level 2)
					Liabilities
					(Level 1)
	Derivative liabilities related to Warrants	$	4,475,345		$	—		$	—	$	4,475,345
	The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities- warrants in the Company’s statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.
	Series A and Series B Preferred Stock Issuances
	On October 14, 2014, the Company’s Board of Directors authorized the sale and issuance of up to 1,250,000 shares of Series A Convertible Preferred Stock (the “Series A”). Also on October 14, 2014, the Company closed a private offering of the Series A and issued 900,000 shares of Series A preferred shares at a stated value of $10.00 per share, generating gross proceeds of approximately $9,000,000. The Company has also granted the purchaser of the Series A and their assignees the option to purchase up to an additional 350,000 shares of Series A prior to February 28, 2015. The purchaser elected to purchase an additional 50,000, 30,000 and 20,000 shares on December 23, 2014, February 10, 2015, and February 26, 2015 generating additional gross proceeds of $500,000, $300,000 and $200,000, respectively. On February 26, 2015, assignees of the purchaser elected to purchase 250,000 shares, generating additional gross proceeds of $2,500,000.
	On December 15, 2014, the Company’s Board of Directors authorized the issuance of 120,000 shares of Series B Convertible Preferred Stock (the “Series B”) in connection with the Company’s exclusive license agreement with Chimerix, Inc., entered into December 17, 2014. (See License Agreement footnote 9). The stated and estimated value of these shares was $10.00 per share.
	There are no stated dividends or redemption features associated with the Series A and B. The Series A and B have voting rights on an as converted basis. Each share of the Series A and B is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. The Series A conversion price is currently $0.48 and the Series B conversion price is currently $1.12, based on 70% of the five day average common share price preceding the date of settlement. If the Company sells common stock or equivalents at an effective price per share that is lower than the conversion price, the Preferred holders conversion price may be reduced to the lower conversion price. The preferred stock is automatically convertible into common stock in the event of a fundamental transaction to the Company. Based on these facts, the Series A and B are classified as permanent equity.
	Beneficial Conversion Feature- Series A and Series B Preferred Stock
	Each share of Series A is convertible into shares of common stock, at any time at the option of the holder at a conversion price of $0.48 per share.  On October 14, 2014, December 23, 2014, February 10, 2015 and February 26, 2015, the date of issuances of the Series A, the publicly traded common stock prices were $0.65, $2.09, $4.50 and $4.50 per share, respectively. Each share of Series B are convertible into shares of common stock at any time at the option of the holder at a conversion price of $1.12 per share. On December 17, 2014, the date of the Series B agreement, the publicly traded common stock price was $1.79 per share.
	Based on the guidance in ASC 470-20-20, the Company determined that a beneficial conversion feature exists, as the effective conversion price for the Series A and Series B preferred shares at issuance was less than the fair value of the common stock into which the preferred shares are convertible. A beneficial conversion feature based on the intrinsic value of the date of issuances for the Series A and Series B shares was $7.8 million and the preferred stock was further discounted by this amount. The beneficial conversion amount of $7.8 million was then accreted back to the preferred stock as a dividend charged to accumulated deficit as the preferred stock was 100% convertible immediately.

Accounting_for_SharedBased_Pay

Accounting for Shared-Based Payments	9 Months Ended
	Mar. 31, 2015
Accounting for Shared-Based Payments
Accounting for Shared-Based Payments
	5. Accounting for Shared-Based Payments
	ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award.
	ContraVir accounts for stock options issued to non-employees based on the fair value of the stock option, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “Equity -Based Payment to Non-Employees” and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.
	ASC Topic 718 requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities. Due to ContraVir’s accumulated deficit position, no excess tax benefits have been recognized. ContraVir accounts for stock options granted to employees and non-employees based on the fair market value of the instrument, using the Black-Scholes option pricing model based on assumptions for expected stock price volatility, term of the option, risk-free interest rate and expected dividend yield, at the grant date.
	On June 3, 2013, ContraVir adopted the 2013 Equity Incentive Plan (the “Plan”). Stock options granted under the Plan typically will vest after three years of continuous service from the grant date and will have a contractual term of ten years. ContraVir has reserved 6,500,000 shares of common stock issuable pursuant to the Plan. As of September 30, 2014 the Company had issued 841,270 options over the authorized number of options in the Plan. As per ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s statement of operations. Stockholder and Board approval was obtained on October 11, 2014, to increase the number of authorized shares. Immediately prior to approval, the liability was revalued, and an additional expense was recorded. Upon approval, the cumulative liability of $119,167 was reversed into additional paid in capital.
	ContraVir recorded the following stock based compensation expense for the periods shown:
		Three months ended						Nine months ended
		March 31,			March 31,			March 31,			March 31,
		2015			2014			2015			2014
	General and administrative	$	168,534		$	101,287		$	317,690		$	102,046
	Research and development	509,382			41,935			871,298			42,007
	Total stock based compensation expense	$	677,916		$	143,223		$	1,188,988		$	144,075
	A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:
		Number of		Exercise Price			Weighted Average			Intrinsic			Weighted Average
		Options		Per Share			Exercise Price			Value			Remaining
							Per Share						Contractual Term
	Balance outstanding, July 1, 2014	2,341,270		$	0.11- $2.37		$	1.61		$	633,200		2.95 years
	Granted	1,497,308		$	1.50 –$2.65		$	1.65		$			—
	Exercised	—		—			—			—			—
	Forfeited	—		$	—		—			—			—
	Balance outstanding, March 31, 2015	3,838,578		$	0.11– $2.65		$	1.63		$	5,570,718		2.25 years
	Exercisable at March 31, 2015	894,090		$	0.11 – $2.35		$	1.22		$	1,663,855
	There were 1,497,308 options granted during the nine months ended March 31, 2015. As of March 31, 2015, the unrecognized compensation cost related to authorized non-vested stock options outstanding, net of expected forfeitures, was approximately $4.2 million to be recognized over a weighted-average remaining vesting period of approximately 2.25 years.
	The following weighted-average assumptions were used in the Black-Scholes valuation model to estimate fair value of stock option awards during the periods indicated.
		Nine Months Ended		Nine Months Ended
		March 31, 2015		March 31, 2014
	Stock price	$1.50 – $3.08		$0.11– $2.36
	Risk-free interest rate	1.39% - 2.29%		1.89 – 2.40%
	Dividend yield	—		—
	Expected volatility	88%		88% – 90%
	Expected term (in years)	6 years		5 – 9.8 years
	Weighted average grant date fair value	$1.30		$1.32
	Stock Price—Effective February 27, 2014, the grant date stock price as of the closing market price of the Company’s common stock is used. Prior to that date, there was no public market for the stock. Management believed that the best alternative indication of stock value is what Synergy paid for the FV-100 Product, in an arms-length transaction, to BMS on August 17, 2012, or $1,000,000. Thus $1,000,000 divided by the 9,000,000 shares then outstanding resulted in a stock price of $0.11 per share.
	Risk-free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of the Company’s stock options.
	Dividend yield—ContraVir has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.
	Expected volatility—Because ContraVir has a limited trading history in its common stock, the Company based expected volatility on that of comparable public development stage biotechnology companies.
	Expected term—ContraVir has had no stock options exercised since inception. The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment, (“SAB No. 107”), which averages an award’s weighted-average vesting period and expected term for “plain vanilla” share options. Under SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.
	In December 2007, the SEC issued SAB No. 110, Share-Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC Topic 718. The Company will use the simplified method until it has the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, the Company has “plain-vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.
	Forfeitures—ASC Topic 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. ContraVir estimated future unvested option forfeitures based on the historical experience of its former parent.

Income_Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2015
Income Taxes
Income Taxes
	6. Income Taxes
	ContraVir records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to ContraVir’s ability to continue as a going concern and utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at March 31, 2015 and June 30, 2014. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statements of operations to offset pre-tax losses.
	ContraVir has no uncertain tax positions subject to examination by the relevant tax authorities as of March 31, 2015 and June 30, 2014 because no tax returns have yet been filed. ContraVir will file U.S. and state income tax returns in jurisdictions with varying statutes of limitations.

Loss_per_Share

Loss per Share	9 Months Ended
	Mar. 31, 2015
Loss per Share
Loss per Share
	7. Loss per Share
	Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC Topic 260”) for all periods presented. In accordance with ASC Topic 260, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In addition, the net loss attributable to common stockholders’ is adjusted for the preferred stock deemed dividends related to the beneficial conversion feature on this instrument for the periods in which the preferred stock is outstanding. The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:
		Three months ended						Nine months ended
		March 31, 2015			March 31, 2014			March 31, 2015			March 31, 2014
	Numerator:
	Net loss	$	(4,397,826	)	$	(9,311,759	)	$	(8,972,676	)	$	(9,661,976	)
	Preferred stock deemed dividend	(3,000,000		)	—			(7,844,643		)	—
	Net loss attributable to common stockholders	$	(7,397,826	)	$	(9,311,759	)	$	(16,817,319	)	$	(9,661,976	)
	Denominator:
	Weighted average common shares outstanding	22,273,397			14,735,551			20,334,797			10,904,873
	Net loss per share of common stock—basic and diluted	$	(0.20	)	$	(0.63	)	$	(0.44	)	$	(0.89	)
	The following outstanding securities at March 31, 2015 and 2014 have been excluded from the computation of diluted weighted shares outstanding, as they would have been anti-dilutive:
		Three months ended				Nine months ended
		March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014
	Common shares issuable upon conversion of Series A preferred stock	26,041,667		—		26,041,667		—
	Common shares issuable upon conversion of Series B preferred stock	1,071,429		—		1,071,429		—
	Stock options	3,838,578		2,142,270		3,838,578		2,142,270
	Total	30,951,674		2,142,270		30,951,674		2,142,270

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2015
Commitments and Contingencies
Commitments and Contingencies
	8.  Commitments and Contingencies
	License Agreement with Chimerix, Inc.
	On December 17, 2014, the Company entered into an exclusive license agreement with Chimerix, Inc. (“Chimerix”) pursuant to which the Company has licensed CMX157 from Chimerix for further clinical development and commercialization. CMX157 is a highly potent analog of the antiviral drug tenofovir DF (Viread®). Under the terms of the agreement, ContraVir licensed CMX157 from Chimerix in exchange for an upfront payment consisting of 120,000 shares of ContraVir Series B Convertible Preferred Stock. In addition, Chimerix is eligible to receive up to approximately $20 million in clinical, regulatory and initial commercial milestone payments in the United States and Europe, as well as royalties and additional milestone payments based on commercial sales in those territories. Either party may terminate the License Agreement upon the occurrence of a material breach by the other party (subject to standard cure periods), or upon certain events involving the bankruptcy or insolvency of the other party. The Company may also terminate the License Agreement without cause on a country by country basis upon sixty days’ prior written notice to Chimerix.
	The fair value of the Preferred B shares exchanged for the license was determined to be equal to the amount paid per share of the Series A, as the provision of the Preferred B shares were the same as the Preferred A Shares, based on an arm’s length transaction.  Therefore, the fair value of the Preferred B shares issued was $10 per share or $1.2 million. The cost of the license was classified as a research and development expense in the amount of $1.2 million as the compound is early stage, has not yet reached technological feasibility and has no alternative use.

Basis_of_Presentation_and_Goin1

Basis of Presentation and Going Concern (Policies)	9 Months Ended
	Mar. 31, 2015
Basis of Presentation and Going Concern
Basis of Presentation
	The unaudited condensed financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and United States generally accepted accounting principles (“GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly ContraVir’s interim financial information. The accompanying unaudited financial statements should be read in conjunction with the audited financial statements as of and for the periods ended June 30, 2014 contained in the Company’s Annual Report on Form 10-K (“Form 10-K”) filed with the Securities and Exchange Commission (“SEC”) on September 29, 2014 and the audited financial statement as of and for the periods ended December 31, 2014 contained in the Company’s Quarterly Report on Form 10-Q (“Form 10-Q”) filed with the SEC on February 12, 2015.
Going Concern
	Going Concern
	As of March 31, 2015, ContraVir had $8.9 million in cash. Net cash used in operating activities was $5.3 million for the nine months ended March 31, 2015.  Net loss for the nine months ended March 31, 2015 was $9.0 million. As of March 31, 2015, ContraVir had working capital of $7.7 million. The Company expects to incur losses for the next several years as it expands its research, development and clinical trials of FV-100 and CMX157. The Company is unable to predict the extent of any future losses or when the Company will become profitable, if at all.
	The statements as of March 31, 2015 and June 30, 2014 have been prepared under the assumption that the Company will continue as a going concern. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt in the Company’s ability to continue as a going concern without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company will be required to raise additional capital to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize its self on unfavorable terms.
Use of Estimates
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Cash
	Cash
	As of March 31, 2015 and June 30, 2014, the amount of cash was approximately $8.9 million and $1.8 million, respectively, consisting of checking accounts held at U.S. commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced losses related to these balances.
Fair Value of Financial Instruments
	Fair Value of Financial Instruments
	ASC Topic 820, Fair Value Measurement (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances.
	ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:
		·	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
		·	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
		·	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
	To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Financial instruments consist of cash, accounts payable and derivative instruments. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments, which were marked to market at the end of each reporting period. See Note 4 for additional information.

Stockholders_Equity_and_Deriva1

Stockholder's Equity and Derivative Liability (Tables)	9 Months Ended
	Mar. 31, 2015
Stockholder's Equity and Derivative Liability
Schedule of changes in derivative financial instruments liability balance
	Date	Description		Warrants		Derivative
						Instrument
						Liability
	7/1/14	Balance of derivative financial instruments liability		4,742,648		$	4,475,345
		Change in fair value of warrants immediately prior to conversion, recognized as change in fair value of derivative instruments- warrants in the statement of operations		—		387,898
		Amounts reclassified to additional paid-in capital		4,742,648		(4,863,243		)
	3/31/15	Balance of derivative financial instruments liability		—		$	—
Schedule of range of assumptions used to determine fair value of warrants
		August 20, 2014
	Estimated fair value of ContraVir common stock	$	1.20
	Expected warrant term (years)	5.46 years
	Risk-free interest rate	1.75		%
	Expected volatility	88		%
	Dividend yield	—
Schedule of fair value of liabilities recognized at fair value on recurring basis
	Description	Balance as of			Quoted Prices			Significant		Significant
		June 30. 2014			in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical			Inputs		(Level 3)
					Assets and			(Level 2)
					Liabilities
					(Level 1)
	Derivative liabilities related to Warrants	$	4,475,345		$	—		$	—	$	4,475,345

Accounting_for_SharedBased_Pay1

Accounting for Shared-Based Payments (Tables)	9 Months Ended
	Mar. 31, 2015
Accounting for Shared-Based Payments
Schedule of stock based compensation expense
		Three months ended						Nine months ended
		March 31,			March 31,			March 31,			March 31,
		2015			2014			2015			2014
	General and administrative	$	168,534		$	101,287		$	317,690		$	102,046
	Research and development	509,382			41,935			871,298			42,007
	Total stock based compensation expense	$	677,916		$	143,223		$	1,188,988		$	144,075
Summary of stock option activity and of changes in stock options outstanding under the Plan
		Number of		Exercise Price			Weighted Average			Intrinsic			Weighted Average
		Options		Per Share			Exercise Price			Value			Remaining
							Per Share						Contractual Term
	Balance outstanding, July 1, 2014	2,341,270		$	0.11- $2.37		$	1.61		$	633,200		2.95 years
	Granted	1,497,308		$	1.50 –$2.65		$	1.65		$			—
	Exercised	—		—			—			—			—
	Forfeited	—		$	—		—			—			—
	Balance outstanding, March 31, 2015	3,838,578		$	0.11– $2.65		$	1.63		$	5,570,718		2.25 years
	Exercisable at March 31, 2015	894,090		$	0.11 – $2.35		$	1.22		$	1,663,855
Schedule of weighted-average assumptions used to estimate fair value of stock option awards
		Nine Months Ended		Nine Months Ended
		March 31, 2015		March 31, 2014
	Stock price	$1.50 – $3.08		$0.11– $2.36
	Risk-free interest rate	1.39% - 2.29%		1.89 – 2.40%
	Dividend yield	—		—
	Expected volatility	88%		88% – 90%
	Expected term (in years)	6 years		5 – 9.8 years
	Weighted average grant date fair value	$1.30		$1.32

Loss_per_Share_Tables

Loss per Share (Tables)	9 Months Ended
	Mar. 31, 2015
Loss per Share
Schedule of computation of basic and diluted net loss per share
		Three months ended						Nine months ended
		March 31, 2015			March 31, 2014			March 31, 2015			March 31, 2014
	Numerator:
	Net loss	$	(4,397,826	)	$	(9,311,759	)	$	(8,972,676	)	$	(9,661,976	)
	Preferred stock deemed dividend	(3,000,000		)	—			(7,844,643		)	—
	Net loss attributable to common stockholders	$	(7,397,826	)	$	(9,311,759	)	$	(16,817,319	)	$	(9,661,976	)
	Denominator:
	Weighted average common shares outstanding	22,273,397			14,735,551			20,334,797			10,904,873
	Net loss per share of common stock—basic and diluted	$	(0.20	)	$	(0.63	)	$	(0.44	)	$	(0.89	)
Schedule of outstanding securities excluded from the computation of diluted weighted shares outstanding
		Three months ended				Nine months ended
		March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014
	Common shares issuable upon conversion of Series A preferred stock	26,041,667		—		26,041,667		—
	Common shares issuable upon conversion of Series B preferred stock	1,071,429		—		1,071,429		—
	Stock options	3,838,578		2,142,270		3,838,578		2,142,270
	Total	30,951,674		2,142,270		30,951,674		2,142,270

Business_Overview_Details

Business Overview (Details) (USD $)	9 Months Ended	4 Months Ended	0 Months Ended
	Mar. 31, 2015	Feb. 26, 2015	Dec. 15, 2014	Feb. 10, 2015	Dec. 23, 2014	Oct. 14, 2014	Dec. 17, 2014
Convertible Preferred Share Issuances
Gross proceeds from sale of stock	$12,500,000
Series A convertible preferred stock
Convertible Preferred Share Issuances
Convertible preferred stock, stated value (in dollars per share)	$10	$10		$10	$10	$10
Series B convertible preferred stock
Convertible Preferred Share Issuances
Convertible preferred stock, stated value (in dollars per share)	$10		10				$10
Preferred Stock | Series A convertible preferred stock
Convertible Preferred Share Issuances
Shares issued (in shares)	1,250,000	1,250,000
Gross proceeds from sale of stock		$12,500,000
Preferred Stock | Series B convertible preferred stock
Convertible Preferred Share Issuances
Issuance of shares (in shares)	120,000		120,000

Basis_of_Presentation_and_Goin2

Basis of Presentation and Going Concern (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Going Concern
Cash	$8,901,298	$2,510,196	$8,901,298	$2,510,196	$1,817,757	$86,716
Net cash used in operating activities			5,333,190	670,640
Net loss	4,397,826	9,311,759	8,972,676	9,661,976
Working capital	7,700,000		7,700,000
Cash
Cash	$8,901,298	$2,510,196	$8,901,298	$2,510,196	$1,817,757	$86,716

Stockholders_Equity_and_Deriva2

Stockholder's Equity and Derivative Liability (Details) (USD $)	9 Months Ended	0 Months Ended
	Mar. 31, 2014	Feb. 04, 2014	Jun. 30, 2014
Stockholders' Deficit
Gross proceeds from sale of units in a private placement	$3,225,000
Expenses related to private placement	15,033
Derivative liabilities related to Warrants			4,475,345
Derivative Instrument Liability | Warrants
Stockholders' Deficit
Derivative liabilities related to Warrants			4,475,345
February 4, 2014 Securities Purchase Agreement
Stockholders' Deficit
Gross proceeds from sale of units in a private placement		3,225,000
Expenses related to private placement		15,000
Number of units sold (in shares)		9,485,294
Number of shares included in each unit		1
Number of warrants included in each unit (in shares)		1
Number of shares called by warrant		0.5
Purchase price (in dollars per unit)		0.34
Expiration term of warrant		6 years
Exercise price of warrants (in dollars per share)		$0.37
February 4, 2014 Securities Purchase Agreement | Derivative Instrument Liability | Warrants
Stockholders' Deficit
Derivative liabilities related to Warrants		$879,557

Stockholders_Equity_and_Deriva3

Stockholder's Equity and Derivative Liability (Details 2) (USD $)	3 Months Ended	9 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Aug. 20, 2014	Feb. 26, 2015	Feb. 10, 2015	Dec. 23, 2014	Dec. 17, 2014	Oct. 14, 2014
Derivative financial instruments liability
Fair Value Restricted Stock				$4,552,924
Components of changes in derivative financial instruments liability
Balance at the beginning of the period		4,475,345
Change in fair value of warrants immediately prior to conversion, recognized as change in fair value of derivative instruments-warrants in the statement of operations	8,846,434	387,898	8,846,434
Common Stock
Derivative financial instruments liability
Restricted common shares issued in exchange of warrants (in shares)		3,794,118		3,794,118
Share price (in dollars per share)	$0.11		$0.11	$1.20	$4.50	$4.50	$2.09	$1.79	$0.65
Derivative Instrument Liability | Warrants
Derivative financial instruments liability
Share price (in dollars per share)				$1.20
Components of changes in derivative financial instruments liability
Balance at the beginning of the period (in shares)		4,742,648
Balance at the beginning of the period		4,475,345
Change in fair value of warrants immediately prior to conversion, recognized as change in fair value of derivative instruments-warrants in the statement of operations		387,898		387,898
Amounts reclassified to additional paid-in capital (in shares)		4,742,648
Amounts reclassified to additional paid-in capital		($4,863,243)		($4,863,243)

Stockholders_Equity_and_Deriva4

Stockholder's Equity and Derivative Liability (Details 3) (Derivative Instrument Liability, Warrants, USD $)	0 Months Ended
	Aug. 20, 2014	Aug. 20, 2014
Derivative Instrument Liability | Warrants
Range of assumptions used to determine the fair value of the warrants
Estimated fair value of ContraVir common stock (in dollars per share)	$1.20	$1.20
Expected warrant term (years)	5 years 5 months 16 days
Risk-free interest rate (as a percent)	1.75%
Expected volatility (as a percent)	88.00%

Stockholders_Equity_and_Deriva5

Stockholder's Equity and Derivative Liability (Details 4) (USD $)	Jun. 30, 2014
Derivative Financial Instruments
Derivative liabilities related to Warrants	$4,475,345
Derivative Instrument Liability | Warrants
Derivative Financial Instruments
Derivative liabilities related to Warrants	4,475,345
Recurring basis | Significant Unobservable Inputs (Level3) | Derivative Instrument Liability | Warrants
Derivative Financial Instruments
Derivative liabilities related to Warrants	4,475,345
Recurring basis | Total Fair Value | Derivative Instrument Liability | Warrants
Derivative Financial Instruments
Derivative liabilities related to Warrants	$4,475,345

Stockholders_Equity_and_Deriva6

Stockholder's Equity and Derivative Liability (Details 5) (USD $)	3 Months Ended	9 Months Ended	0 Months Ended	6 Months Ended	0 Months Ended	4 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Oct. 14, 2014	Mar. 31, 2015	Feb. 26, 2015	Feb. 26, 2015	Feb. 10, 2015	Dec. 23, 2014	Dec. 17, 2014	Dec. 15, 2014	Aug. 20, 2014	Mar. 31, 2014
Series A and Series B Convertible Preferred Stock
Gross proceeds from sale of stock		$12,500,000
Amount preferred stock discounted	3,000,000	7,844,643
Series A convertible preferred stock
Series A and Series B Convertible Preferred Stock
Shares authorized			1,250,000
Convertible preferred stock, stated value (in dollars per share)	$10	$10	$10	$10	$10	$10	$10	$10
Additional number of shares available for purchase by the underwriters			350,000
Conversion price (in dollars per share)				$0.48
Percentage of five day average common share price used as basis for conversion price	70.00%	70.00%		70.00%
Series A convertible preferred stock | Assignees of purchaser
Series A and Series B Convertible Preferred Stock
Shares issued (in shares)					250,000
Gross proceeds from sale of stock					2,500,000
Series B convertible preferred stock
Series A and Series B Convertible Preferred Stock
Shares authorized										120,000
Convertible preferred stock, stated value (in dollars per share)	$10	$10		$10					$10	$10
Conversion price (in dollars per share)				$1.12
Percentage of five day average common share price used as basis for conversion price	70.00%	70.00%		70.00%
Preferred Stock | Series A convertible preferred stock
Series A and Series B Convertible Preferred Stock
Shares issued (in shares)		1,250,000				1,250,000
Gross proceeds from sale of stock						12,500,000
Preferred Stock | Series A convertible preferred stock | Purchaser
Series A and Series B Convertible Preferred Stock
Shares issued (in shares)			900,000		20,000		30,000	50,000
Gross proceeds from sale of stock			9,000,000		200,000		300,000	500,000
Common Stock
Series A and Series B Convertible Preferred Stock
Stock price (in dollars per share)			$0.65		$4.50	$4.50	$4.50	$2.09	$1.79		$1.20	$0.11
Accumulated Deficit
Series A and Series B Convertible Preferred Stock
Charge to accumulated deficit related to beneficial conversion feature		$7,844,643

Accounting_for_SharedBased_Pay2

Accounting for Shared-Based Payments (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended	13 Months Ended
	Oct. 11, 2014	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2015	Sep. 30, 2014
Accounting for Shared-Based Payments
Excess tax benefits recognized (in dollars)		$0
Number of shares of common stock reserved for issuance, pursuant to the Plan		6,500,000		6,500,000			6,500,000
Number of options issued over authorized options (in shares)								841,270
Reversal of liability into additional paid in capital	119,167
Stock based compensation expense
Total stock based compensation expense (in dollars)		677,916	143,223	1,188,988	144,075
General and administrative
Stock based compensation expense
Total stock based compensation expense (in dollars)		168,534	101,287	317,690	102,046
Research and development
Stock based compensation expense
Total stock based compensation expense (in dollars)		509,382	41,935	871,298	42,007
Stock options
Accounting for Shared-Based Payments
Vesting period for stock options granted under the Plan		3 years
Contractual term of stock options		10 years
Number of Options
Balance outstanding at the beginning of the period (in shares)				2,341,270
Granted (in shares)				1,497,308
Exercised (in shares)							0
Balance outstanding at the end of the period (in shares)		3,838,578		3,838,578		2,341,270	3,838,578
Exercisable at the end of the period		894,090		894,090			894,090
Weighted Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in dollars per share)				$1.61
Granted (in dollars per share)				$1.65
Balance outstanding at the end of the period (in dollars per share)		$1.63		$1.63		$1.61	$1.63
Exercisable at the end of the period		$1.22		$1.22			$1.22
Intrinsic Value
Balance outstanding at the beginning of the period (in dollars)				633,200
Balance outstanding at the end of the period (in dollars)		5,570,718		5,570,718		633,200	5,570,718
Exercisable at the end of the period		1,663,855		1,663,855			1,663,855
Weighted Average Remaining Contractual Term (in years)
Balance outstanding at the beginning of the period				2 years 3 months		2 years 11 months 12 days
Balance outstanding at the end of the period				2 years 3 months		2 years 11 months 12 days
Unrecognized compensation cost related to non-vested stock options outstanding
Unrecognized compensation cost related to non-vested stock (in dollars)		$4,200,000		$4,200,000			$4,200,000
Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized		2 years 3 months
Stock options | Minimum
Exercise Price Per Share
Balance outstanding at the beginning of the period (in dollars per share)				$0.11		$0.11
Granted (in dollars per share)				$1.50
Balance outstanding at the end of the period (in dollars per share)				$0.11		$0.11
Exercisable at the end of the period		$0.11		$0.11			$0.11
Stock options | Maximum
Exercise Price Per Share
Balance outstanding at the beginning of the period (in dollars per share)				$2.65		$2.37
Granted (in dollars per share)				$2.65
Balance outstanding at the end of the period (in dollars per share)				$2.65		$2.37
Exercisable at the end of the period		$2.35		$2.35			$2.35

Accounting_for_SharedBased_Pay3

Accounting for Shared-Based Payments (Details 2) (USD $)	0 Months Ended	9 Months Ended		13 Months Ended
	Aug. 17, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Jun. 30, 2014	Feb. 26, 2015	Feb. 10, 2015	Dec. 23, 2014	Dec. 17, 2014	Oct. 14, 2014	Aug. 20, 2014
Weighted-average assumptions to determine fair value of stock option awards
Shares outstanding (in shares)		22,273,397	9,000,000	22,273,397	18,479,279
Common Stock
Weighted-average assumptions to determine fair value of stock option awards
Stock price (in dollars per share)			$0.11			$4.50	$4.50	$2.09	$1.79	$0.65	$1.20
Synergy
Weighted-average assumptions to determine fair value of stock option awards
Amount Synergy paid for FV-100 Product (in dollars)	$1,000,000
Stock options
Weighted-average assumptions to determine fair value of stock option awards
Expected volatility (as a percent)		88.00%
Expected term (in years)		6 years
Weighted average grant date fair value (in dollars per share)		$1.30	$1.32
Stock options exercised (in shares)				0
Stock options | Minimum
Weighted-average assumptions to determine fair value of stock option awards
Stock price (in dollars per share)		$1.50	$0.11	1.5
Risk-free interest rate (as a percent)		1.39%	1.89%
Expected volatility (as a percent)			88.00%
Expected term (in years)			5 years
Stock options | Maximum
Weighted-average assumptions to determine fair value of stock option awards
Stock price (in dollars per share)		$3.08	$2.36	3.08
Risk-free interest rate (as a percent)		2.29%	2.40%
Expected volatility (as a percent)			90.00%
Expected term (in years)			9 years 9 months 18 days

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014
Income Taxes
Income tax benefits	$0	$0
Amount of uncertain tax positions	$0	$0

Loss_per_Share_Details

Loss per Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Numerator
Net loss	($4,397,826)	($9,311,759)	($8,972,676)	($9,661,976)
Preferred stock deemed dividend	-3,000,000		-7,844,643
Net loss attributable to common stockholders	($7,397,826)	($9,311,759)	($16,817,319)	($9,661,976)
Denominator
Weighted average common shares outstanding (in shares)	22,273,397	14,735,551	20,334,797	10,904,873
Net loss per share of common stock-basic and diluted (in dollars per share)	($0.20)	($0.63)	($0.44)	($0.89)
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	30,951,674	2,142,270	30,951,674	2,142,270
Series A convertible preferred stock
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	26,041,667		26,041,667
Series B convertible preferred stock
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	1,071,429		1,071,429
Stock options
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	3,838,578	2,142,270	3,838,578	2,142,270

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	9 Months Ended	0 Months Ended
	Mar. 31, 2015	Dec. 15, 2014	Dec. 17, 2014
License Agreement
Cost of license as research and development expense	$1,200,000
Series B convertible preferred stock
License Agreement
Convertible preferred stock, stated value (in dollars per share)	$10	10	$10
Stated value of preferred stock issued	1,200,000
Preferred Stock | Series B convertible preferred stock
License Agreement
Upfront payment (in shares)	120,000	120,000
License Agreement | Chimerix, Inc.
License Agreement
Maximum payments to be made for clinical, regulatory and initial commercial milestones			20,000,000
Minimum prior written notice period in order to terminate agreement			60 days
Cost of license as research and development expense			1,200,000
License Agreement | Chimerix, Inc. | Preferred Stock | Series B convertible preferred stock
License Agreement
Upfront payment (in shares)			120,000
Stated value of preferred stock issued			$1,200,000